Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
Imatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML associated with additional cytogenetic abnormalities at diagnosis among black Africans? For this, we retrospectively studied 27 cases of CML associated with additional cyto...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2013/901589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553969191223296 |
|---|---|
| author | Tolo Diebkilé Aïssata Duni Sawadogo Clotaire Nanho Boidy Kouakou N'dogomo Meité N'Dhatz Emeuraude Ayémou Roméo Sekongo Yassongui Mamadou Paul Kouéhion Konan Mozart Gustave Koffi Ibrahima Sanogo |
| author_facet | Tolo Diebkilé Aïssata Duni Sawadogo Clotaire Nanho Boidy Kouakou N'dogomo Meité N'Dhatz Emeuraude Ayémou Roméo Sekongo Yassongui Mamadou Paul Kouéhion Konan Mozart Gustave Koffi Ibrahima Sanogo |
| author_sort | Tolo Diebkilé Aïssata |
| collection | DOAJ |
| description | Imatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML associated with additional cytogenetic abnormalities at diagnosis among black Africans?
For this, we retrospectively studied 27 cases of CML associated with additional cytogenetic abnormalities, diagnosed in the department of clinical hematology of the University Hospital of Yopougon in Côte d'Ivoire, from May 2005 to October 2011.
The age of patients ranged from 13 to 68 years, with a mean age of 38 years and a sex ratio of 2. Patients were severely symptomatic with a high Sokal score of 67%. CML in chronic phase accounted for 67%. The prevalence of additional cytogenetic abnormalities was 29.7%. There were variants of the Philadelphia chromosome (18.5%), trisomy 8 (14.8%), complex cytogenetic abnormalities (18.5%), second Philadelphia chromosome (14.8%), and minor cytogenetic abnormalities (44.4%). Complete hematologic remission was achieved in 59%, with 52% of major cytogenetic remission. The outcome was fatal in 37% of patients. Death was related in 40% to hematologic toxicity and in 30% to acutisation. The median survival was 40 months. |
| format | Article |
| id | doaj-art-c18279b347dd4b068ba9aa4c68e20918 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-c18279b347dd4b068ba9aa4c68e209182025-02-03T05:52:48ZengWileyAdvances in Hematology1687-91041687-91122013-01-01201310.1155/2013/901589901589Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black AfricansTolo Diebkilé Aïssata0Duni Sawadogo1Clotaire Nanho2Boidy Kouakou3N'dogomo Meité4N'Dhatz Emeuraude5Ayémou Roméo6Sekongo Yassongui Mamadou7Paul Kouéhion8Konan Mozart9Gustave Koffi10Ibrahima Sanogo11Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Biological Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireDepartment of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'IvoireImatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML associated with additional cytogenetic abnormalities at diagnosis among black Africans? For this, we retrospectively studied 27 cases of CML associated with additional cytogenetic abnormalities, diagnosed in the department of clinical hematology of the University Hospital of Yopougon in Côte d'Ivoire, from May 2005 to October 2011. The age of patients ranged from 13 to 68 years, with a mean age of 38 years and a sex ratio of 2. Patients were severely symptomatic with a high Sokal score of 67%. CML in chronic phase accounted for 67%. The prevalence of additional cytogenetic abnormalities was 29.7%. There were variants of the Philadelphia chromosome (18.5%), trisomy 8 (14.8%), complex cytogenetic abnormalities (18.5%), second Philadelphia chromosome (14.8%), and minor cytogenetic abnormalities (44.4%). Complete hematologic remission was achieved in 59%, with 52% of major cytogenetic remission. The outcome was fatal in 37% of patients. Death was related in 40% to hematologic toxicity and in 30% to acutisation. The median survival was 40 months.http://dx.doi.org/10.1155/2013/901589 |
| spellingShingle | Tolo Diebkilé Aïssata Duni Sawadogo Clotaire Nanho Boidy Kouakou N'dogomo Meité N'Dhatz Emeuraude Ayémou Roméo Sekongo Yassongui Mamadou Paul Kouéhion Konan Mozart Gustave Koffi Ibrahima Sanogo Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans Advances in Hematology |
| title | Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans |
| title_full | Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans |
| title_fullStr | Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans |
| title_full_unstemmed | Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans |
| title_short | Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans |
| title_sort | imatinib mesylate effectiveness in chronic myeloid leukemia with additional cytogenetic abnormalities at diagnosis among black africans |
| url | http://dx.doi.org/10.1155/2013/901589 |
| work_keys_str_mv | AT tolodiebkileaissata imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT dunisawadogo imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT clotairenanho imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT boidykouakou imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT ndogomomeite imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT ndhatzemeuraude imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT ayemouromeo imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT sekongoyassonguimamadou imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT paulkouehion imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT konanmozart imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT gustavekoffi imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans AT ibrahimasanogo imatinibmesylateeffectivenessinchronicmyeloidleukemiawithadditionalcytogeneticabnormalitiesatdiagnosisamongblackafricans |